Media Release 14 November 2025 Inaugural diabetes report reveals the stark reality of a silent pandemic, but early intervention could save millions A new report by leading Australian pathology provider, Healius, has revealed the diabetes hotspots…
Media Release
14 November 2025
Inaugural diabetes report reveals the stark reality of a silent pandemic, but early
intervention could save millions
A new report by leading Australian pathology provider, Healius, has revealed the diabetes hotspots across
the country and the areas where early intervention in pre-diabetes could save the health system millions.
The inaugural Diabetes Watch report by Healius Pathology, released on World Diabetes Day, identifies
federal electorates returning high levels of pre-diabetes or diabetes across Australia.
“Diabetes has become one of the most pressing health challenges in Australia, often described as a ‘silent
pandemic’ due to its widespread impact and long-term consequences,” Healius Pathology Chief Executive
Officer, Paul Anderson said.
“This inaugural report provides a startling roadmap of the areas which are most at risk.”
Drawing on five million pathology tests from across the country over the last two years, the report identifies
the most at-risk federal electorates. By specifically calling out the incidence of pre-diabetes, this report is a
call to action for local representatives, GPs and patients alike.
Pre-diabetes does not have to become diabetes, and yet the early signs of risk are too often missed.
Many Australians with pre-diabetes are unaware of their condition and, without intervention, up to 60 per
cent will develop Type 2 Diabetes within five years.
To support GPs in detecting and managing pre-diabetes and diabetes, Healius Pathology will soon launch a
free Diabetes Audit tool for health practitioners.
This free tool will provide primary health care physicians with data to better manage diabetes in the
community.
Healius Pathology Group Executive of Digital Health, Prasad Arav, who led the report and the development
of the upcoming Diabetes Audit tool, said, "Type 2 Diabetes is a chronic health condition, but often it is
preventable. Prevention requires early intervention by primary care physicians, informed by pathology
testing data”.
“We not only have the data but we have developed a digital tool that will help GPs monitor key patient
biomarkers, like HbA1c, and influence patients to take proactive measures at the pre -diabetic stage.
“Not only can this improve health outcomes but it also has the potential to save huge amounts of time and
money across the healthcare system. We are proud of the work we are doing to help the community."
Pre-diabetes and diabetes can be diagnosed via a simple blood test that shows a patient's average blood
sugar (glucose) levels over the previous two to three months.
Healius has conducted five million HbA1c tests across Australia over the past two years.
“The HbA1c test is a powerful diagnostic tool that can help GPs change the course of their patient’s
disease. By acting now, we can change the future of diabetes in Australia - one test, one patient and one
community at a time,” Mr Anderson said.
The findings underscore the crucial role of digital health tools, including integrated test reporting, digital
patient engagement and data-driven clinical insights, in identifying and managing diabetes earlier and more
effectively.
“This report will allow us to track changes in diabetes diagnosis across the country. Our hope is that this will
inform pre-emptive policy and support for those living with the condition,” Mr Anderson said.
View the full report here.
Quotes attributable to Chief Executive Officer, Paul Anderson
“The good news is that with early detection, support and lifestyle changes, we can significantly reduce the
number of people suffering from the condition, creating better health outcomes for Australians and reducing
the burden on our healthcare system.”
“Pathology plays a crucial role in providing evidence-based healthcare because it offers vital data to inform
early intervention and management of the disease.”
“Together, through data-driven insights and strategic prevention efforts, we can make a meaningful
difference in reducing the impact of diabetes on Australians.”
Quotes attributable to Director of Chemical Pathology, Dorevitch Pathology, Dr Ken Sikaris
“There is a strong argument that diabetes is simply our greatest health problem because of its link to
hypertension and renal disease, abnormal lipids and cardiovascular risk, as well as stroke — Type 2
diabetes is just the tip of this iceberg.”
“As the diabetes pandemic shows little sign of improving, particularly if we follow the US lead, the
preventative aspects of pathology testing should be foremost in Australia.”
Quotes attributable to Western Diagnostic Pathology Medical Director and Head of Biochemistry, Dr
Johan Conradie
“Early intervention to prevent the onset of Type 2 diabetes can significantly reduce long -term organ damage
across multiple biological systems.”
“Pathology biomarkers such as HbA1c for glucose control, ALT for liver health, and eGFR for kidney
function provide an essential early-warning system for clinicians. These biomarkers also assist in the early
detection of metabolic dysfunction–associated steatotic liver disease (MASLD), where even subtle ALT
elevations may reflect hepatic metabolic stress well before structural liver damage appears.”
“Together, these insights support earlier intervention and help curb the rising burden of chronic metabolic
disease in Australia.”
ENDS
About Healius Pathology
Healius Pathology is one of Australia’s leading providers of private medical laboratory and pathology
services. Operating nationally under a variety of established state-based and specialty brands, Healius
Pathology provides leading medical laboratory and pathology services across key diagnostic activities. Each
year, approximately one in four Medicare funded pathology tests are processed in our laboratories. Healius
Pathology’s services extend from exclusively servicing some of Australia’s largest and most complex private
and public hospitals to regional areas and remote Indigenous communities.
Media contact: Laura Downey, [email protected], 0427 827 928
Healius Limited ACN 064 530 516 | Level 22, Liberty Place, 161 Castlereagh Street NSW 2060 | healius.com.au | Phone 02 9432 9 400 | Fax
02 9432 9447